Hungarian government prepares to buy back Richter bonds to keep its 25% stake

11 May 2009

The Socialist Party in Hungary has proposed an amendment to the State Assets Act in a bid to ensure that the government keeps its 25% stake in  the country's biggest drug manufacturer, Richter Gedeon. The legislative  changes would allow - and effectively force - it to buy back bonds  convertible for Richter shares. The move has effectively ended recent  speculation about Richter's future ownership after the  government-controlled convertible bonds expire in September this year.

The Hungarian government sold its 25% stake in Richter in September  2004 through a convertible bond and it is up to it to decide whether the  holders would receive cash or Richter shares when the convertible bonds  expire. Provided the proposed legislation passes the Budapest  Parliament, the state could continue to remain the biggest shareholder.  To pass the bill the minority socialist government will require the  support of some opposition Members of Parliament too.

Richter welcomed the proposal, saying that "the government keeping its  stake in the company would ensure the stable ownership structure"  necessary for the pharmaceutical manufacturer to continue its growth  strategy. According to Richter spokeswoman Zsuzsa Beke, buying back the  bonds could cost the government as much as 200 billion forint ($976.0  million). With the recently-introduced economic austerity program in  Hungary, it is hard to see where this money would come from.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight